In contrast to statins, the risk of diabetes with fibrates was not clearly studied. This study investigates a putative signal of diabetes associated with the use of fibrates using the World Health Organization (WHO) global individual case safety reports database, VigiBase â . We included all reports registered until the 31st December 2017 in VigiBase â to measure the risk of reporting 'hyperglycemia or new onset of diabetes' (SMQ term) compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for fibrates, statins, and the combination fibrates + statins. The likelihood that diabetes resulted from statin-fibrate interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and after exclusion of putative competitive (hyperglycemic) drugs. We included 19 149 patients exposed to fibrates (without statins), 177 323 to statins (without fibrates) and 3 247 to statins plus fibrates. In contrast to statins (ROR = 1.75, 95% CI 1.72-1.78), no association was found for fibrates (ROR = 0.76, 95% CI 0.71-0.82). The ROR value was lower for the combination statins plus fibrates (ROR = 1.46, 95% CI 1.28-1.67). Similar trends were found in sensitivity analyses. This study, performed in the real conditions of use, failed to find a signal of diabetes with fibrates. It strengths the association previously described with statin without any evidence for a statin-fibrate DDI.
A B S T R A C T
In contrast to statins, the risk of diabetes with fibrates was not clearly studied. This study investigates a putative signal of diabetes associated with the use of fibrates using the World Health Organization (WHO) global individual case safety reports database, VigiBase â . We included all reports registered until the 31st December 2017 in VigiBase â to measure the risk of reporting 'hyperglycemia or new onset of diabetes' (SMQ term) compared with all other reports [as a reporting odds ratio (ROR 95% CI)] for fibrates, statins, and the combination fibrates + statins. The likelihood that diabetes resulted from statin-fibrate interaction was also estimated. According to the interaction additive model, a ROR value for coexposure exceeding the sum of the RORs estimated for each individual class of drug supports a potential drug-drug interaction (DDI). To assess the stability of our results, we performed several sensitivity analyses, according to outcome definition and after exclusion of putative competitive (hyperglycemic) drugs. We included 19 149 patients exposed to fibrates (without statins), 177 323 to statins (without fibrates) and 3 247 to statins plus fibrates. In contrast to statins (ROR = 1.75, 95% CI 1.72-1.78), no association was found for fibrates (ROR = 0.76, 95% CI 0.71-0.82). The ROR value was lower for the combination statins plus fibrates (ROR = 1.46, 95% CI 1.28-1.67). Similar trends were found in sensitivity analyses. This study, performed in the real conditions of use, failed to find a signal of diabetes with fibrates. It strengths the association previously described with statin without any evidence for a statin-fibrate DDI. Due to these conflicting data, this study was performed to investigate a putative association between diabetes and use of fibrates by analyzing data from a large pharmacovigilance database. Results were compared with those obtained with statins alone. We also tested the hypothesis that a statin/fibrate interaction could potentiate the risk of diabetes.
I N T R O D U C T I O N

M E T H O D S
Data from Vigibase â , the WHO pharmacovigilance database including more than 16 million reports of individual case safety reports (ICSRs) forwarded to the WHO Uppsala Monitoring Center by national pharmacovigilance systems from over 110 countries around the world since 1967 [6], were used for this disproportionality analysis (case/non-case method) [7, 8] To assess the stability of our results, we performed several sensitivity analyses, according outcome definition and individual drugs. The first one used the System Organ Class (SOC) classification with the High Level Term (HLT) 'Diabetes mellitus and hyperglycemic conditions'. The second focused only on fenofibrate and atorvastatin, that is, the fibrate and the statin the most frequently prescribed. Third, in order to reduce the indication bias [7, 8, 11] , we directly compared fibrates (without statins) versus statins (without fibrates) using the SMQ classification and then the SOC one. Finally, in order to reduce the competition bias [7, 8, 11] , we performed other analyses excluding from the analysis drugs known to induce hyperglycemia/diabetes [12, 13] , that is, antiretrovirals (J05), atypical antipsychotics (N05AE, N05AF, N05AG, N05AH, N05AX, N05AL), calcineurin inhibitors (L04D), tacrolimus (in D11AH), low and high ceiling diuretics (C03A, C03B, CO3C), beta-blocking agents (C07), thyroid preparations (H3A), and glucocorticoids (H02AB, H02B).
Fibrates included in the study were beclofibrate, bezafibrate, binifibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate, gemfibrozil, plafibride, ronifibrate, simfibrate and theofibrate and statins atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin (synonym for itastatin), pravastatin, rosuvastatin, and simvastatin. Finally, olanzapine (N05AH), an atypical antipsychotic known to induce hyperglycemia [12, 13] , was selected as positive control.
Results are shown as reporting odds ratios (ROR) with their 95% confidence interval which compares the odds of exposure to drugs of interest (fibrates alone, statins alone, and statins plus fibrates) between cases and non-cases with 1 as the threshold ROR value [7, 8] . Comparisons between groups were made using chi-square test. Fibrates, statins, and diabetes
R E S U L T S
Using the SMQ classification, use of statins, but not fibrates, was significantly associated with reports of diabetes ( Table II) . The disproportionality analysis also found an association between fibrate plus statin exposure and occurrence of diabetes ( Table II) . The ROR value of the coexposure was lower than the sum of the RORs estimated for each individual class of drug (Table II) . ROR value for the direct comparison of statins versus fibrates was 4.44 (95% CI 3.84-5.13) and statins versus statins plus fibrates 2.39 (95% CI 1.85-3.09).
Sensitivity analyses using the SOC classification (Table III) found similar tendencies. Similar significant trends were also found after exclusion of competing drugs whatever the used classification: SMQ (Table IV) or SOC ( Table V) . The sole exception was the association found with fibrates (without statin) using the SOC classification ( Table V) .
Reporting odds ratio value for olanzapine, chosen as a positive control, was 10.03 [95% CI 9.78-10.30].
D I S C U S S I O N
The present study was performed to investigate a putative signal of diabetes with the fibrates. An association was found with statins but not with fibrates. We also failed to find any evidence for a statin-fibrate interaction.
Some points need to be discussed. First, the present study investigates a putative association between diabetes reports and fibrates exposure in Vigibase â . There are relatively few data discussing this risk of diabetes with fibrates [5] . From a pharmacodynamic point of view, one could expect an effect of fibrates on glucose metabolism as, such as thiazolidinediones, fibrates are Peroxisome Proliferator-Activated Receptor (PPAR) agonists. However, fibrates acts on PPAR alpha and thiazolidinediones on the PPAR gamma receptor [14, 15] . In the FIELD study, the change in HbA1C was negligible but no statistical analysis was performed [16] . In the Lee's study, the number of new diabetes with fibrates was low (n = 145) but the lack of a control group does not allow any conclusion [17] . Tenenbaum found a reduced number of diabetes over a 6-year follow-up in patients with impaired fasting glucose and coronary artery disease [18] . Finally, other data failed to show any association between the L162V single nucleotide polymorphism of the peroxisome proliferator activated receptor alpha gene and type 2 diabetes [19] . In a previous study describing drugs associated with reports of hyperglycemia in the French pharmacovigilance database, we did not find any signal with fibrates [12] . Similarly, in their 2015's literature review, Fathallah's group failed to find any paper about fibrates and hyperglycemia or diabetes [13] . The present study failed to find a pharmacovigilance signal with fibrates in contrast to the results found with statins. Second, the present study strengths the association previously described between statin exposure and occurrence of diabetes [1-4]. In a previous study in Vigibase â , we found that atorvastatin was the statin with the higher signal followed by rosuvastatin, lovastatin, and simvastatin. The lower signal was found with cerivastatin and fluvastatin [20] . Several mechanisms were proposed to explain this association [21] : decrease in insulin sensitivity, reduced translocation of glucose transporter 4, decrease in coenzyme Q10, or direct toxicity on pancreatic cells.
Another interesting point is the results of drug-drug interaction. In fact, ROR values for coexposure to statins plus fibrates were always lower than the sum of the RORs estimated for statins alone and fibrates alone. According to the interaction additive model, this does not support a drug-drug interaction [11] . As far as we know, this putative interaction was not previously investigated.
Our study suffers from the inherent limitations of all pharmacovigilance study [7, 8, 11] , the first being under-or selective reporting [22] . However, as it is known that underreporting is similar within the same pharmacotherapeutic group of drugs [23] , the comparison between statins and fibrates is valuable. In fact, pharmacovigilance databases were not built to exhaustively record all reports of ADRs but to detect signals like [7, 8] . Drug doses, duration of exposure, and lifestyle risk factors were not included in the study as these data are not exhaustively recorded in Vigibase
In contrast, our study has several important strengths [7, 8, 11] . First, as it was performed in the largest pharmacovigilance database in the world, we were able to include almost 200 000 patients treated with statins and/or fibrates leading to results with a high statistical power. Second, Vigibase â registers data from over 110 countries, in all representing over 90% of the world's population, thus giving universal data in the context of real world. Third, we used a validated method, the case/ non-case one. Investigating a putative disproportionality between reports, this method was previously found to be able to detect rare signals of ADRs [7, 8, 11] . The positive association found with olanzapine, selected as a reference drug for this ADR, confirms the validity of our approach. The same is true for statins, which are also included in the study as a control. Fourth, we performed a direct comparison between statins and fibrates in order to minimize the indication bias which is frequent in case non-case studies [7, 8, 11] : this analysis confirms the clear difference between the two groups of hypolipidemic drugs. Finally, we also performed sensitivity analyses excluding competitors, that is, the main drugs known to be associated with hyperglycemia and/or diabetes [12, 13] , which could distort the signal leading to false positive results. After taking into account this competition bias [7, 8, 11] , similar trends were found showing the consistency of our results.
In conclusion, the present pharmacoepidemiological study failed to find a signal of diabetes with fibrates in the real word context. Moreover, for the first time, we described the lack of statin-fibrate interaction for the risk of diabetes. These results suggest the interest of fibrates instead of statins in at risk diabetes patients.
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